Clinical Trials Logo

Leukoencephalopathies clinical trials

View clinical trials related to Leukoencephalopathies.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06276504 Not yet recruiting - Clinical trials for Progressive Multifocal Leukoencephalopathy

Pembrolizumab in Progressive Multifocal Leukoencephalopathy (PML) in Immunocompromised Patients Without HIV Infection

PENALTY
Start date: April 2024
Phase: Phase 2/Phase 3
Study type: Interventional

This study aims to assess the efficacy and safety of pembrolizumab in immunocompromised patients with progressive multifocal leukoencephalopathy (PML). This phase II, multicenter, single-arm study includes patients with an underlying cause of immunosuppression hardly reversible, i.e. not the patients with HIV nor those receiving biologics for chronic inflammatory diseases. Patients will receive intravenous pembrolizumab (2 mg/kg, maximum 200 mg) at month 0, 1 and 2 (total of three doses). The primary endpoint will be achieving at least one negative result of JCV viral load in cerebrospinal fluid (CSF) within the M0 to M3 period.

NCT ID: NCT05541549 Not yet recruiting - Clinical trials for Progressive Multifocal Leukoencephalopathy

A Phase 2 Study Evaluating JCPyV-specific T Cell Therapy for PML

ASCEND-JC
Start date: February 2023
Phase: Phase 2
Study type: Interventional

This is a randomized, double-blinded, Phase 2 trial in patients with PML due to JCPyV. Patients will receive treatment with a matched virus-specific T-cell product (CE VST01-JC) or placebo, and will then be monitored for response to therapy.